Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease by Yi Sun (118759)

“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i>_d,RIPK1 = 8.6 nM, <i>K</i>_d,RIPK3 > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC₅₀ = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”

siRNA Knockdown of PKCδ decreases phosphorylation of VEEV capsid. by Brian D. Carey (6092747)

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)

Log reactivation results for exposures by 222 nm or 265 nm with or without UV-A 365 nm pre-treatment. by Daniel Ma (12698752)

24-hr treatment with 100nM M64HCl, 10μM PF573228, the combination of 100nM M64HCl and 10μM PF573228, 10μM PD98059, or the combination of 100nM M64HCl and 10μM PD98059 in migrating... by Sema Oncel (10152053)

Subjects:

24-hr treatment with 100nM M64HCl, 10μM PF573228, the combination of 100nM M64HCl and 10μM PF573228, 10μM PD98059, or the combination of 100nM M64HCl and 10μM PD98059 in migrating... by Sema Oncel (10152053)

Subjects:

Fluorescent intensity at 520 nm (RNase A/B) and 556 nm (DNase I) versus time for nucleases in DI water lysed with Lyse-It at 30% and 50% power for varying time. by Tonya M. Santaus (5559077)

“…<b>(A)</b> 20 pM RNase A <b>(B)</b> 46 pM RNase B, <b>(C)</b> 10.5 nM DNase I. As microwave power and time increase, nuclease activity decreases.…”

The decrease in OD_320nm over time in spectrophotometric ATPase activity assays. by Kai-Yin Chau (18504230)

Results isoprenaline (30nM) experiment. by L. Cao (3526226)

Conditional <i>Aff4</i> knockout decreases fat mass in mice. by Yaqian Chen (1711576)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

RDV and EIDD2801 EC₅₀ and fold-change in VeroE6-ACE2-TMPRSS2. by Agnieszka M. Szemiel (10196243)

Far-UV CD spectra from 180nm to 260nm for blank HSA and HSA in Abraxane and self-made nanoparticles. by Yue Gao (263086)

Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer by Fan-Fan Shang (16953264)

Subjects:

A representative stress-strain curve of a 3D printed PCL/30% (wt.) nHAp scaffold obtained after compressive testing displaying the linear region to derive E () and the point pertai... by Zahra Yazdanpanah (10038944)

Results of the fitting process of the basic epidemiological model (i.e., without vaccinations). by Matthias Horn (78815)

Genes whose expression was decreased by 100 nM ouabain by more than 1.3-fold. by Larisa V. Smolyaninova (3600053)